David Hermann

5.0k total citations · 2 hit papers
46 papers, 3.6k citations indexed

About

David Hermann is a scholar working on Infectious Diseases, Surgery and Pharmacology. According to data from OpenAlex, David Hermann has authored 46 papers receiving a total of 3.6k indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Infectious Diseases, 9 papers in Surgery and 9 papers in Pharmacology. Recurrent topics in David Hermann's work include Tuberculosis Research and Epidemiology (8 papers), Anesthesia and Sedative Agents (8 papers) and Hormonal and reproductive studies (6 papers). David Hermann is often cited by papers focused on Tuberculosis Research and Epidemiology (8 papers), Anesthesia and Sedative Agents (8 papers) and Hormonal and reproductive studies (6 papers). David Hermann collaborates with scholars based in United States, United Kingdom and Germany. David Hermann's co-authors include Keith T. Muir, Steven L. Shafer, Talmage D. Egan, Harry J. M. Lemmens, Charles F. Minto, Jaap W. Mandema, John F. Hoke, Elizabeth Youngs, Pedro L. Gambús and Thomas W. Schnider and has published in prestigious journals such as Nature Medicine, PLoS ONE and The Journal of Clinical Endocrinology & Metabolism.

In The Last Decade

David Hermann

46 papers receiving 3.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Influence of Age and Gender on the Pharmacokinetics and Pharmacodynamics of Remifentanil

1997 910 citations Charles F. Minto, Thomas W. Schnider et al. Anesthesiology profile →
The Pharmacokinetics of the New Short-acting Opioid Remifentanil (GI87084B) in Healthy Adult Male Volunteers

1993 445 citations Talmage D. Egan, Harry J. M. Lemmens et al. Anesthesiology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
David Hermann United States	23	1.9k	1.1k	699	574	500	46	3.6k
Jennifer M. Hunter United Kingdom	28	1.5k 0.8×	903 0.8×	486 0.7×	502 0.9×	573 1.1×	86	2.4k
G. Hempelmann Germany	37	684 0.4×	2.0k 1.8×	245 0.4×	615 1.1×	1.3k 2.5×	338	5.6k
Jaap W. Mandema United States	30	1.4k 0.8×	744 0.7×	576 0.8×	400 0.7×	361 0.7×	59	3.5k
C. A. Shanks United States	25	931 0.5×	641 0.6×	172 0.2×	264 0.5×	243 0.5×	125	1.9k
Pieter Colin Netherlands	21	1.0k 0.6×	492 0.4×	459 0.7×	508 0.9×	260 0.5×	63	2.3k
Johannes H. Proost Netherlands	35	1.3k 0.7×	794 0.7×	451 0.6×	331 0.6×	278 0.6×	144	3.6k
Wei Mei China	24	214 0.1×	622 0.6×	72 0.1×	136 0.2×	219 0.4×	123	3.1k
Elaine Douglas United Kingdom	24	1.4k 0.7×	572 0.5×	558 0.8×	316 0.6×	287 0.6×	42	2.4k
U Haglund Sweden	39	93 0.0×	3.0k 2.6×	210 0.3×	327 0.6×	449 0.9×	198	6.2k
Andrew C. Bernard United States	25	118 0.1×	977 0.9×	75 0.1×	301 0.5×	292 0.6×	132	3.2k

Countries citing papers authored by David Hermann

Since Specialization

Citations

This map shows the geographic impact of David Hermann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Hermann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Hermann more than expected).

Fields of papers citing papers by David Hermann

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Hermann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Hermann. The network helps show where David Hermann may publish in the future.

Co-authorship network of co-authors of David Hermann

This figure shows the co-authorship network connecting the top 25 collaborators of David Hermann. A scholar is included among the top collaborators of David Hermann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Hermann. David Hermann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Dartois, Véronique, Valerie Mizrahi, Radojka M. Savić, et al.. (2025). Strategies for shortening tuberculosis therapy. Nature Medicine. 31(6). 1765–1775. 4 indexed citations

Zhang, Cindy, Thomas Conrad, David Hermann, et al.. (2024). Clofazimine pharmacokinetics in HIV‐infected adults with diarrhea: Implications of diarrheal disease on absorption of orally administered therapeutics. CPT Pharmacometrics & Systems Pharmacology. 13(3). 410–423. 2 indexed citations

Gumbo, Tawanda, Shashikant Srivastava, Devyani Deshpande, et al.. (2023). Hollow-fibre system model of tuberculosis reproducibility and performance specifications for best practice in drug and combination therapy development. Journal of Antimicrobial Chemotherapy. 78(4). 953–964. 7 indexed citations

Kriel, Belinda, Laura E. Via, Yin Cai, et al.. (2022). Sputum lipoarabinomannan (LAM) as a biomarker to determine sputum mycobacterial load: exploratory and model-based analyses of integrated data from four cohorts. BMC Infectious Diseases. 22(1). 327–327. 11 indexed citations

Arinaminpathy, Nimalan, Gabriela B. Gomez, Kuldeep Singh Sachdeva, et al.. (2020). The potential deployment of a pan-tuberculosis drug regimen in India: A modelling analysis. PLoS ONE. 15(3). e0230808–e0230808. 7 indexed citations

Polak, Sebastian, Klaus Romero, Alexander Berg, et al.. (2018). Quantitative approach for cardiac risk assessment and interpretation in tuberculosis drug development. Journal of Pharmacokinetics and Pharmacodynamics. 45(3). 457–467. 18 indexed citations

Imperial, Marjorie Z., Payam Nahid, Patrick Phillips, et al.. (2018). A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis. Nature Medicine. 24(11). 1708–1715. 191 indexed citations

Hermann, David, et al.. (2018). Evaluating the safety, tolerability, pharmacokinetics and efficacy of clofazimine in cryptosporidiosis (CRYPTOFAZ): study protocol for a randomized controlled trial. Trials. 19(1). 456–456. 10 indexed citations

Hermann, David, Mario Mezler, Michaela Müller, et al.. (2013). Synthetic Aβ oligomers (Aβ1–42 globulomer) modulate presynaptic calcium currents: Prevention of Aβ-induced synaptic deficits by calcium channel blockers. European Journal of Pharmacology. 702(1-3). 44–55. 28 indexed citations

10.

Frye, Stephen V., H. Neal Bramson, David Hermann, et al.. (2006). Discovery and Development of GG745, a Potent Inhibitor of Both Isozymes of of 5α-Reductase. Kluwer Academic Publishers eBooks. 11. 393–422. 12 indexed citations

11.

Miller, Raymond, Wayne Ewy, Brian Corrigan, et al.. (2005). How Modeling and Simulation Have Enhanced Decision Making in New Drug Development. Journal of Pharmacokinetics and Pharmacodynamics. 32(2). 185–197. 99 indexed citations

12.

Mandema, Jaap W., David Hermann, Wen‐Ping Wang, et al.. (2005). Model-based development of gemcabene, a new lipid-altering agent. The AAPS Journal. 7(3). E513–E522. 53 indexed citations

13.

Olsson, Per, David Hermann, Margareta Hammarlund‐Udenaes, & Mats O. Karlsson. (1999). Validation of a population pharmacokinetic/pharmacodynamic model for 5α-reductase inhibitors. European Journal of Pharmaceutical Sciences. 8(4). 291–299. 10 indexed citations

14.

Glass, Peter S. A., Irène A. Iselin-Chaves, David K. Goodman, Elizabeth R. DeLong, & David Hermann. (1999). Determination of the Potency of Remifentanil Compared with Alfentanil Using Ventilatory Depression as the Measure of Opioid Effect. Anesthesiology. 90(6). 1556–1563.. 58 indexed citations

15.

Minto, Charles F., Thomas W. Schnider, Talmage D. Egan, et al.. (1997). Influence of Age and Gender on the Pharmacokinetics and Pharmacodynamics of Remifentanil. Anesthesiology. 86(1). 10–23. 910 indexed citations breakdown →

16.

Kapila, Atul, Peter S. A. Glass, James Jacobs, et al.. (1995). Measured Context-sensitive Half-times of Remifentanil and Alfentanil. Anesthesiology. 83(5). 968–975. 318 indexed citations

17.

Hermann, David, George E. Dukes, Elizabeth K. Hussey, et al.. (1992). Comparison of Verapamil, Diltiazem, and Labetalol on the Bioavailability and Metabolism of Imipramine. The Journal of Clinical Pharmacology. 32(2). 176–183. 22 indexed citations

18.

Dukes, George E., William D. Heizer, Yong Han, et al.. (1992). Influence of Gastrointestinal Site of Drug Delivery on the Absorption Characteristics of Ranitidine. Pharmaceutical Research. 9(9). 1190–1194. 53 indexed citations

19.

Hutchinson, Richard A., et al.. (1991). Pharmacy Research in Academic Institutions. American Journal of Pharmaceutical Education. 55(1). 40–45. 8 indexed citations

20.

Higginbotham, Eve J., et al.. (1989). The Effect of Caffeine on Intraocuular Pressure in Glaucoma Patents. Ophthalmology. 96(5). 624–626. 47 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact